DekaBank Deutsche Girozentrale boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 21.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 320,301 shares of the company’s stock after buying an additional 57,629 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Zoetis were worth $20,138,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Assetmark Inc. boosted its position in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after buying an additional 85 shares in the last quarter. Guardian Life Insurance Co. of America boosted its position in Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd purchased a new position in Zoetis during the first quarter worth $111,000. Advisory Services Network LLC purchased a new position in Zoetis during the first quarter worth $112,000. Finally, First Interstate Bank boosted its position in Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. 94.51% of the stock is owned by institutional investors.

Zoetis Inc. (ZTS) opened at 59.73 on Friday. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. The stock has a 50 day moving average of $62.20 and a 200 day moving average of $58.00. The stock has a market cap of $29.21 billion, a price-to-earnings ratio of 33.76 and a beta of 1.02.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The company’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. Equities analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-has-20-14-million-position-in-zoetis-inc-zts/1478131.html.

A number of analysts have issued reports on the stock. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the company a “buy” rating in a report on Monday, July 17th. Deutsche Bank AG restated a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Tuesday, June 20th. Hilliard Lyons started coverage on shares of Zoetis in a report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 target price on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price target on shares of Zoetis in a research note on Friday, July 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average price target of $64.78.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.